NRIX logo

Nurix Therapeutics Inc. (NRIX)

$14.24

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NRIX

Market cap

$1.56B

EPS

2.3

P/E ratio

--

Price to sales

63.09

Dividend yield

--

Beta

1.798163

Price on NRIX

Previous close

$14.73

Today's open

$14.80

Day's range

$14.11 - $14.87

52 week range

$12.43 - $28.23

Profile about NRIX

CEO

Arthur T. Sands

Employees

317

Headquarters

Brisbane, CA

Exchange

NASDAQ Global Market

Shares outstanding

109249814

Issue type

Common Stock

NRIX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on NRIX

Nurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer

Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions

news source

GlobeNewsWire • Nov 11, 2026

news preview

Nurix Therapeutics to Participate in Upcoming Investor Conferences

BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: UBS Global Biopharma Conference Tuesday, November 17, 2026, at 2:40 p.m.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that new and updated clinical data from its ongoing Phase 1a/1b study evaluating bexobrutideg (NX-5948), the Company's investigational oral Bruton's tyrosine kinase (BTK) degrader, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15, 2026 in New Orleans, Louisiana.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development

Shares of Nurix Therapeutics crashed Wednesday after Sanofi unexpectedly scrapped an experimental eczema drug that two were codeveloping.

news source

Investors Business Daily • Nov 4, 2026

news preview

Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexobrutideg's superiority over JAYPIRCA in relapsed/refractory CLL/SLL. Potential Accelerated Approval for bexobrutideg in 3rd-line+ r/r CLL/SLL is supported by promising phase 1/2 data and ongoing pivotal trials.

news source

Seeking Alpha • Oct 14, 2026

news preview

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

news source

GlobeNewsWire • Oct 12, 2026

news preview

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a year ago.

news source

Zacks Investment Research • Oct 12, 2026

news preview

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study evaluating bexobrutideg, an investigational oral Bruton's tyrosine kinase (BTK) degrader, in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

news source

GlobeNewsWire • Oct 7, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Nurix Therapeutics Inc.

Open an M1 investment account to buy and sell Nurix Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NRIX on M1